Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 6
2004 4
2005 5
2006 7
2007 9
2008 7
2009 4
2010 10
2011 8
2012 8
2013 12
2014 11
2015 7
2016 11
2017 10
2018 11
2019 8
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Results by year
Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: pautier p. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Among authors: pautier p. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Clinical Trial.
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Delanoy N, et al. Among authors: pautier p. Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4. Lancet Haematol. 2019. PMID: 30528137
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. Moore KN, et al. Among authors: pautier p. Future Oncol. 2018 Jul;14(17):1669-1678. doi: 10.2217/fon-2017-0646. Epub 2018 Feb 9. Future Oncol. 2018. PMID: 29424243 Free article. Clinical Trial.
Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature.
Bentivegna E, Maulard A, Pautier P, Chargari C, Gouy S, Morice P. Bentivegna E, et al. Among authors: pautier p. Fertil Steril. 2016 Oct;106(5):1195-1211.e5. doi: 10.1016/j.fertnstert.2016.06.032. Epub 2016 Jul 16. Fertil Steril. 2016. PMID: 27430207 Review.
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González-Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N. Oza AM, et al. Among authors: pautier p. Int J Gynecol Cancer. 2017 Jan;27(1):50-58. doi: 10.1097/IGC.0000000000000836. Int J Gynecol Cancer. 2017. PMID: 27749456 Free PMC article. Clinical Trial.
Lymphadenectomy in Advanced Ovarian Neoplasms.
Morice P, Pautier P, Gouy S. Morice P, et al. Among authors: pautier p. N Engl J Med. 2019 Jun 6;380(23):2274. doi: 10.1056/NEJMc1904411. N Engl J Med. 2019. PMID: 31167062 No abstract available.
Rucaparib in the landscape of PARP inhibition in ovarian cancer.
Colomba E, Pautier P, Pommeret F, Leary A. Colomba E, et al. Among authors: pautier p. Expert Rev Anticancer Ther. 2019 Jun;19(6):437-446. doi: 10.1080/14737140.2019.1607302. Epub 2019 May 16. Expert Rev Anticancer Ther. 2019. PMID: 30977683 Review.
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I. Rousset-Jablonski C, et al. Among authors: pautier p. Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. Bull Cancer. 2018. PMID: 29397916 French.
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Lavoue V, et al. Among authors: pautier p. Bull Cancer. 2019 Apr;106(4):354-370. doi: 10.1016/j.bulcan.2019.01.014. Epub 2019 Mar 6. Bull Cancer. 2019. PMID: 30850152 Free article. Review. French.
144 results
Jump to page